- Coordinator
- Institut National De La Sante Et De La Recherche Medicale, France
- Runs
- 1 March 2025 to 28 February 2029
- Status
- Running
- EU funding
- €3.7m
- Total cost
- —
- Partners
- 31 organisations in 10 countries
- Type
- Marie Skłodowska-Curie Action
- Grant agreement
- 101169266
What the project is doing
In the project's own words, from its summary on CORDIS.
Rare diseases, though individually infrequent, collectively pose important challenges for patients, clinicians and researchers in terms of diagnostics, healthcare and treatment. Myotonic Dystrophy (DM), the most predominant inherited muscular dystrophy in adults, impacts 60,000-70,000 individuals in Europe. Its complex genetic and clinical variability result in a lack of robust genotype-phenotype correlations, which complicates the understanding of tissue-specific disease mechanisms, the development of effective therapies and the stratification of patients into well-defined clinical groups for clinical trial purposes.
In recent years, Antisense Oligonucleotides (ASO) have emerged as promising therapeutics, notably in neuromuscular disorders. However, previous clinical trials in DM have failed due the reduced efficacy and bioavailability of the ASO tested. ENTRY-DM aims to train 14 DCs in translational research, through the combination of basic and clinical competencies across multiple disciplines, as well as strong soft and transferable skills.
Our interdisciplinary network seeks to enhance scientific and technological knowledge, spanning from disease mechanisms, ASO design and delivery strategies, to clinical trial preparedness, using innovative multidisciplinary approaches and best practices. The consortium includes experts in DM research, bioengineering of model systems for preclinical drug screening, ASO chemistry, as well as clinical and neuropsychological assessment.
Close collaborations with multi-sectoral partners will address the challenges in technology transfer, providing high-quality bench-to-bedside training to the next generation of researchers. Through these efforts, ENTRY-DM will catalyze ASO therapeutic development towards upcoming impeding clinical trials, establishing solid foundations for future clinical applications, increased investment and entrepreneurship ventures in the field of DM and other related diseases.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Institut National De La Sante Et De La Recherche Medicale | Paris | France | Coordinator |
| Sib Swiss Institute of Bioinformatics | Genf | Switzerland | Associatedpartner |
| Ludwig-Maximilians-Universitaet Muenchen | Planegg | Germany | Participant |
| Agencia Estatal Consejo Superior De Investigaciones Cientificas | Madrid | Spain | Participant |
| Arthex Biotech SL | Valencia | Spain | Associatedpartner |
| Biobam Bioinformatics SL | Valencia | Spain | Associatedpartner |
| Fundacio Institut De Bioenginyeria De Catalunya | Barcelona | Spain | Participant |
| Universitat De Barcelona | Barcelona | Spain | Associatedpartner |
| Universitat De Valencia | Valencia | Spain | Participant |
| Association Institut De Myologie | Paris | France | Associatedpartner |
| Centre D'etude Des Cellules Souches | Corbeil-Essonnes | France | Participant |
| Ecrin European Clinical Research Infrastructure Network | Paris | France | Associatedpartner |
| Euro-Dyma | Paris | France | Associatedpartner |
| Sorbonne Universite | Paris | France | Associatedpartner |
| Universite D'evry-Val D'essone | Evry | France | Associatedpartner |
| Universite Paris Cite | Paris | France | Participant |
| Genartis SRL | Verona | Italy | Participant |
| Universita Degli Studi Di Roma La Sapienza | Roma | Italy | Associatedpartner |
| Universita Degli Studi Di Roma Tor Vergata | Roma | Italy | Participant |
| Universita Degli Studi Di Verona | Verona | Italy | Associatedpartner |
| Eatris Eric | Amsterdam | Netherlands | Associatedpartner |
| Stichting Radboud Universitair Medisch Centrum | Nijmegen | Netherlands | Participant |
| Stichting Radboud Universiteit | Nijmegen | Netherlands | Associatedpartner |
| Uniwersytet Im. Adama Mickiewicza Wpoznaniu | Poznan | Poland | Participant |
| Goeteborgs Universitet | Goeteborg | Sweden | Associatedpartner |
| The Chancellor, Masters and Scholars of the University of Oxford | Oxford | United Kingdom | Associatedpartner |
| Myotonic Dystrophy Foundation | Oakland | United States | Associatedpartner |
| Sanofi Genzyme | Cambridge | United States | Associatedpartner |
| The Regents of the University of California | Oakland | United States | Associatedpartner |
| University of Florida | Gainesville | United States | Associatedpartner |
| Virginia Commonwealth University | Richmond, VA | United States | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI